ライフサイエンスコーパス: balloon angioplasty

1 ts underwent DCB angioplasty or conventional balloon angioplasty.

2 intervals in 74 patients undergoing elective balloon angioplasty.

3 trocardiograms (ECGs) in patients undergoing balloon angioplasty.

4 ial fibroblasts to neointima formation after balloon angioplasty.

5 rs and 14 days after rat carotid artery (CA) balloon angioplasty.

6 riority of DCB angioplasty over conventional balloon angioplasty.

7 on or sham radiation (n=8) immediately after balloon angioplasty.

8 ignal transduction prevents restenosis after balloon angioplasty.

9 ling on subsequent vessel behavior following balloon angioplasty.

10 delivery to modify arterial remodeling after balloon angioplasty.

11 py for reducing neointimal hyperplasia after balloon angioplasty.

12 at hospital admission than patients who had balloon angioplasty.

13 40%, respectively (P:<0.01), at day 14 after balloon angioplasty.

14 restenosis at the target site after stent or balloon angioplasty.

15 C) is characteristic of restenosis following balloon angioplasty.

16 oliferation and in neointima formation after balloon angioplasty.

17 G and subsequent PCI rates, as compared with balloon angioplasty.

18 carotid artery after deep arterial injury by balloon angioplasty.

19 tes for both strategies compared to standard balloon angioplasty.

20 nt outcomes for coronary stent placement and balloon angioplasty.

21 al reseeding on restenosis eight weeks after balloon angioplasty.

22 in the saphenous artery of the baboon after balloon angioplasty.

23 nt of restenosis in response to injury after balloon angioplasty.

24 rocedures in diabetic patients compared with balloon angioplasty.

25 ased restenosis and late morbidity following balloon angioplasty.

26 short- and long-term benefits compared with balloon angioplasty.

27 osis in comparison to historical controls of balloon angioplasty.

28 Coronary bypass surgery or balloon angioplasty.

29 ssion of vascular lumen volume in vivo after balloon angioplasty.

30 in attenuating regrowth of endothelium after balloon angioplasty.

31 in rat carotid arteries that are injured by balloon angioplasty.

32 as attempted in 23 patients after successful balloon angioplasty.

33 culture and reduces arterial restenosis post-balloon angioplasty.

34 ventitia was markedly increased 3 days after balloon angioplasty.

35 ns using a dedicated bifurcation stent or SB balloon angioplasty.

36 n was observed in 5% of patients during test balloon angioplasty.

37 moral artery revascularization compared with balloon angioplasty.

38 remained superior compared with conventional balloon angioplasty.

39 taxel-coated balloon angioplasty or uncoated balloon angioplasty.

40 d binary restenosis compared to conventional balloon angioplasty.

41 edom from repeat interventions than standard balloon angioplasty.

42 ase that limits the use of bypass surgery or balloon angioplasty.

43 major role in vascular wall remodeling after balloon angioplasty.

44 CABG rate was also significantly higher for balloon angioplasty (10.81% vs. 7.25%, p<0.001).

45 %), and they were more commonly treated with balloon angioplasty (116/128, 91%), whereas lesions loca

46 analyses, mortality was similar after plain balloon angioplasty (12.6%) and paclitaxel-coated balloo

47 .4%), and 104 were treated with conventional balloon angioplasty (18.5%).

48 quent PCIs was also significantly higher for balloon angioplasty (19.6% vs. 14.3%, p<0.0001).

49 tient CABG rate was significantly higher for balloon angioplasty (2.72% vs. 1.66%, p<0.0001), and the

50 which progressively declined from plain old balloon angioplasty (341% increase) to bare metal stent

51 esions who were treated by stenting (61%) or balloon angioplasty (39%) received 0 (control), 16, 20,

52 e absolute rates at 5 years were 46.1% after balloon angioplasty, 40.1% after PCI with stents, and 9.

53 l atherectomy (3.7% vs. 13.5%), conventional balloon angioplasty (73% vs. 50%) and rotational atherec

54 on angioplasty (12.6%) and paclitaxel-coated balloon angioplasty (9.6%; HR=0.84 [95% CI, 0.66-1.06],

55 r MI rate: 12.7% for stent-placebo, 7.8% for balloon angioplasty-abciximab, and 6.2% for the stent-ab

56 -placebo, 162 to stent-abciximab, and 156 to balloon angioplasty-abciximab.

57 dial infarction was independently reduced by balloon angioplasty/abciximab (hazard ratio, 0.51; P<0.0

58 abciximab (hazard ratio, 0.58; P<0.001), and balloon angioplasty/abciximab (hazard ratio, 0.74; P=0.0

59 plasty/placebo, 14.2%; stent/placebo, 15.8%; balloon angioplasty/abciximab, 7.6%; and stent/abciximab

60 hyperglycemia as well as abrasions following balloon angioplasty all lead to endothelial dysfunction

61 or greater compared with those treated with balloon angioplasty alone (n=145; HR 0.43, 0.19-0.97; p=

62 el-coated balloon angioplasty is superior to balloon angioplasty alone for treatment of drug-eluting

63 ievement of an initial stent-like result via balloon angioplasty alone may not appreciably reduce the

64 enous anastomotic stenosis to undergo either balloon angioplasty alone or balloon angioplasty plus pl

65 th paclitaxel-coated balloon was superior to balloon angioplasty alone with a late loss of 0.43 +/- 0

66 tenting, rather than provisional stenting or balloon angioplasty alone, improves clinical outcomes in

67 tly enhance myocardial perfusion compared to balloon angioplasty alone, underlying the similar long-t

68 atients, whereas 1985-1986 patients received balloon angioplasty alone.

69 ting stent restenosis compared with uncoated balloon angioplasty alone.

70 f DCB angioplasty compared with conventional balloon angioplasty (also known as plain old balloon ang

71 us coronary intervention (PCI) with standard balloon angioplasty among patients with multivessel coro

72 ; an increase in the MLD in both zones after balloon angioplasty and a significant versus slight redu

73 01) and 7.8 percent in the group assigned to balloon angioplasty and abciximab (hazard ratio, 0.67; 9

74 lacebo, stent implantation and abciximab, or balloon angioplasty and abciximab.

75 was measured in 42 patients before and after balloon angioplasty and again after stent placement.

76 Studies from the balloon angioplasty and bare metal stent eras have demon

77 some disadvantages and limitations of plain balloon angioplasty and bare-metal stents, some limitati

78 mined late arterial responses 6 months after balloon angioplasty and beta-radiation in normal pig cor

79 cycle for the prevention of restenosis after balloon angioplasty and bypass vein graft disease.

80 istologically distinct from restenosis after balloon angioplasty and comprised largely of neointima f

81 Coronary interventions, including balloon angioplasty and coronary stent implantation, are

82 rates for patients undergoing single-vessel balloon angioplasty and coronary stent placement.

83 t of carotid atherosclerosis, beginning with balloon angioplasty and evolving to the use of stents; a

84 cell proliferation induced by carotid artery balloon angioplasty and ligation to reduce blood flow.

85 plasty routine stent implantation or initial balloon angioplasty and provisional stenting.

86 An alternative approach is to do balloon angioplasty and provisionally use stents only to

87 r stents expand the arterial lumen more than balloon angioplasty and reduce rates of restenosis after

88 hat in unstented arteries that had undergone balloon angioplasty and showed similar proteoglycan depo

89 r iatrogenic vascular injury associated with balloon angioplasty and stent deployment.

90 Restenosis after balloon angioplasty and stenting (BAS) remains an unsolv

91 Balloon angioplasty and stenting are the mainstays of en

92 Balloon angioplasty and stenting form the backbone of en

93 a focus on lesion modification to facilitate balloon angioplasty and stenting has underpinned major a

94 ne the long-term benefit of widely performed balloon angioplasty and stenting procedures.

95 evascularization is perceived as superior to balloon angioplasty and surgical revascularization, but

96 Although the relative merits of conventional balloon angioplasty and thrombolysis have been evaluated

97 o compensate for further plaque growth after balloon angioplasty and thus show a proportional increas

98 processes such as arterial restenosis after balloon angioplasty and tumor-induced angiogenesis.

99 esults of infrapopliteal interventions using balloon angioplasty and/or bare stents are limited by a

100 metal stents, -24.2% (-32.2 to -16.4) versus balloon angioplasty, and -31.8% (-44.8 to -18.6) versus

101 induced in Yorkshire albino swine (n=6) with balloon angioplasty, and 4 weeks later MRI of the corona

102 Ischemic complications after balloon angioplasty are associated with pre- and post-pr

103 Autologous vein grafts and balloon angioplasty are still commonly used for arterial

104 Nowadays stent placement has replaced balloon angioplasty as the most commonly performed percu

105 ) of coronary stenting compared with primary balloon angioplasty as treatment for AMI.

106 ority of whom had diffuse lesions, underwent balloon angioplasty, atherectomy, additional stenting, o

107 r restenosis after intervention using either balloon angioplasty (BA) alone or BA with stenting.

108 this study was to determine the efficacy of balloon angioplasty (BA) by comparing the immediate and

109 ions were randomized to treatment with plain balloon angioplasty (BA) followed by PEB angioplasty and

110 utcomes of children randomized to surgery or balloon angioplasty (BA) for native coarctation (CoA).

111 ertaken to evaluate the long-term results of balloon angioplasty (BA) for postsurgical recoarctation

112 correlating with the hemodynamic response to balloon angioplasty (BA) in patients with drug-resistant

113 deficient (ApoE(null)) mice without and with balloon angioplasty (BA) injury, a model of restenosis.

114 We hypothesized that after balloon angioplasty (BA) of atherosclerotic arteries, se

115 safety and efficacy of surgical, stent, and balloon angioplasty (BA) treatment of native coarctation

116 s at the discretion of individual operators: balloon angioplasty (BA), repeat stent or rotational ath

117 e in CoA can be an alternative to surgery or balloon angioplasty (BA).

118 B with non-DCB devices (such as conventional balloon angioplasty, bare-metal stents, or drug-eluting

119 d less bleeding than heparin during coronary balloon angioplasty but has not been widely tested durin

120 reduce the restenosis rate as compared with balloon angioplasty, but in-stent restenosis continues t

121 epatic artery stenosis and were treated with balloon angioplasty by radiology.

122 stents improve immediate and late results of balloon angioplasty by tacking up dissections and preven

123 After balloon angioplasty, c-FLIP protein is rapidly down-regu

124 Balloon angioplasty can be safely performed in infants,

125 caused by distention of the arterial wall by balloon angioplasty can result in apoptosis and vascular

126 f the study was to determine whether cutting balloon angioplasty (CBA) has advantages over other moda

127 in diabetic patients undergoing conventional balloon angioplasty compared with coronary artery bypass

128 er coronary intervention predominantly using balloon angioplasty correlates with late cardiac events

129 A coronary balloon angioplasty cyclic flow variation (CFV) model wa

130 Drug-coated balloon angioplasty (DCBA) was shown to be superior to s

131 Balloon angioplasty decreased from 83.8% to 68.5%, DCA i

132 diagnostic modalities may facilitate optimal balloon angioplasty delivery and postprocedural care.

133 After balloon angioplasty, distal flow was restored, resulting

134 ized 2082 AMI patients to either stenting or balloon angioplasty, each +/- abciximab.

135 ts with AMI randomized to either stenting or balloon angioplasty, each with or without abciximab, had

136 Balloon angioplasty eliminated (16 patients) or reduced

137 Balloon angioplasty eliminates or improves IVUS findings

138 Finally, some are strong proponents of balloon angioplasty, even in the neonatal period, recogn

139 Compared with balloon angioplasty, everolimus-eluting stent (hazard ra

140 Previous trials testing stents compared with balloon angioplasty excluded patients with complex lesio

141 Before balloon angioplasty, flow in the aorta distal to the ste

142 ng stenting without balloon predilation with balloon angioplasty followed by stenting.

143 Clinical outcomes after direct balloon angioplasty for acute myocardial infarction were

144 contributed to the disappointing results of balloon angioplasty for complex infrainguinal arterial d

145 provements in stent technology as adjunct to balloon angioplasty for multivessel coronary disease, se

146 The efficacy of balloon angioplasty for native CoA during infancy beyond

147 ospective review of 68 infants who underwent balloon angioplasty for native CoA.

148 Balloon angioplasty for native coarctation of the aorta

149 efficacy of elective stent implantation and balloon angioplasty for new lesions in small coronary ar

150 or asymptomatic individuals and percutaneous balloon angioplasty for patients with indications for in

151 ber of patients have indicated the safety of balloon angioplasty for the treatment of stenoses in the

152 ACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Fem

153 ls, PCB angioplasty was superior to uncoated balloon angioplasty for treatment of bare-metal stent (B

154 Despite widespread application of balloon angioplasty for treatment of coronary artery dis

155 ht to define the impact of paclitaxel-coated balloon angioplasty for treatment of drug-eluting stent

156 ic and long-term results of debulking versus balloon angioplasty for treatment of true bifurcation le

157 67.4%) than in the percutaneous transluminal balloon angioplasty group (44.9%, P=0.002).

158 of patients in the percutaneous transluminal balloon angioplasty group and 77% in the nitinol stent g

159 greater in the stent-graft group than in the balloon-angioplasty group (32% vs. 16%, P=0.03 by the lo

160 greater in the stent-graft group than in the balloon-angioplasty group (51% vs. 23%, P<0.001), as was

161 nosis, which occurred more frequently in the balloon-angioplasty group (P<0.001).

162 ry restenosis at 6 months was greater in the balloon-angioplasty group than in the stent-graft group

163 /-0.72 mm in the cryoplasty and conventional balloon angioplasty groups, respectively (p=0.02).

164 93 (37%) patients assigned balloon angioplasty had at least one stent placed becaus

165 Local administration of L-arginine after balloon angioplasty has been shown to enhance NO generat

166 94, the number of patients treated only with balloon angioplasty has decreased nationally, whereas th

167 r stents improve myocardial perfusion beyond balloon angioplasty has not been investigated.

168 -stage renal disease undergoing conventional balloon angioplasty have reduced procedural success and

169 31% of patients and suboptimal results from balloon angioplasty in 18%.

170 diation with LPRLL prevents restenosis after balloon angioplasty in an atherosclerotic rabbit model.

171 ed to placebo or tranilast before undergoing balloon angioplasty in both the left anterior descending

172 success and reduce restenosis compared with balloon angioplasty in patients with acute coronary synd

173 stent placement to percutaneous transluminal balloon angioplasty in patients with peripheral artery d

174 ly reduced neointimal hyperplasia induced by balloon angioplasty in rabbit carotid arteries in vivo.

175 PCI was done with balloon angioplasty in six trials and with bare-metal st

176 Patients having balloon angioplasty in the Bypass Angioplasty Revascular

177 presented a major advancement over plain old balloon angioplasty in the management of coronary artery

178 Two weeks after balloon angioplasty in the rat carotid artery, elevated

179 rior angiographic and clinical outcomes than balloon angioplasty in vessels slightly smaller than 3 m

180 d in neointima formation in rat artery after balloon angioplasty in vivo.

181 er stent placement and high pressure adjunct balloon angioplasty) in 382 lesions in 291 patients trea

182 t placement reduces restenosis compared with balloon angioplasty, in-stent restenosis remains a major

183 achieved in 40.7% of patients randomized to balloon angioplasty, including 38.5% and 42.7% assigned

184 Balloon angioplasty increased the CoA diameter from 2.7+

185 gs have a broad application in prevention of balloon angioplasty-induced restenosis.

186 vascular homeostatic molecule that prevents balloon angioplasty-induced stenosis via antiproliferati

187 with arterialized vein graft vasculopathy or balloon angioplasty-induced vessel injury.

188 ach) sequences were created by intracoronary balloon angioplasty inflation-deflation.

189 ed proliferation and neointimal formation in balloon angioplasty-injured rat carotid arteries (0.172

190 Common carotid artery (CCA) balloon angioplasty injury was performed in rats.

191 that is expressed in VSMCs by allograft and balloon angioplasty injury.

192 ere administered for 14 days after oversized balloon angioplasty injury.

193 Balloon angioplasty is a safe, effective and durable met

194 Balloon angioplasty is a well-accepted modality for the

195 Drug-coated balloon angioplasty is associated with favorable results

196 Balloon angioplasty is effective, with low morbidity, no

197 Balloon angioplasty is inferior to all drug-eluting trea

198 These results suggest that restenosis after balloon angioplasty is markedly influenced by thrombin-m

199 Balloon angioplasty is not different from cutting balloo

200 Paclitaxel-coated balloon angioplasty is superior to balloon angioplasty a

201 e mechanism contributing to restenosis after balloon angioplasty is the loss of the EC lining.

202 2-hour infusion of r-hirudin at the time of balloon angioplasty limits restenosis in atherosclerotic

203 After balloon angioplasty, locally expressed tumor necrosis fa

204 Intentional fracture with UHP balloon angioplasty may be considered when treating sten

205 Patients at low risk for restenosis after balloon angioplasty may not derive additional benefit fr

206 A variety of noxious stimuli, including balloon angioplasty, may compromise EC integrity, thereb

207 f adventitial cells into the neointima after balloon angioplasty might have an important role in vasc

208 vascular response to injury in a rat carotid balloon angioplasty model.

209 l bioavailability, in the rat carotid artery balloon angioplasty model.

210 luminal stenosis in a porcine femoral artery balloon angioplasty model.

211 luminal stenosis in a porcine femoral artery balloon angioplasty model.

212 rtality was compared between 3 groups; plain balloon angioplasty (N=2104) versus paclitaxel-coated ba

213 ngioplasty (N=2104) versus paclitaxel-coated balloon angioplasty (N=3543), bare-metal stenting (N= 20

214 ho underwent intervention for recoarctation (balloon angioplasty [n = 26] and surgical repair of reco

215 In restenosis after balloon angioplasty, negative remodeling is a major mech

216 Balloon angioplasty of in-stent restenosis may, therefor

217 The 1-year restenosis rate after balloon angioplasty of long lesions in below-the-knee ar

218 Balloon angioplasty of native CoA is effective and safe

219 e delivery of 12, 14, or 16 Gy at 2 mm after balloon angioplasty of stenoses of native coronary vesse

220 mononuclear cells, and the animals underwent balloon angioplasty of the common carotid artery.

221 bbits (n=5 to 6 per group) were subjected to balloon angioplasty of the common carotid artery.

222 tage over stenting one branch and performing balloon angioplasty of the other branch.

223 in situ with PKH26, a fluorescent dye, after balloon angioplasty of the rat common carotid artery.

224 stenting of the main branch with our without balloon angioplasty of the side branch offers hemodynami

225 The patient underwent balloon angioplasty of the stenotic SVC segment with res

226 Balloon angioplasty of true coronary bifurcation lesions

227 , lesion location, and additional treatment (balloon angioplasty or atherectomy).

228 rs of increased all-cause mortality included balloon angioplasty or bare-metal stent placement compar

229 ed trial of tirofiban in patients undergoing balloon angioplasty or directional atherectomy within 72

230 However, prior trials compared CABG with balloon angioplasty or older generation stents, and it i

231 balloon angioplasty (also known as plain old balloon angioplasty or POBA).

232 ion of restenosis in coronary arteries after balloon angioplasty or stent implantation.

233 identify New York patients undergoing either balloon angioplasty or stent placement between July 1, 1

234 n of coronary artery (CA) compression during balloon angioplasty or stent placement in the overlying

235 gle main branch stenting without side branch balloon angioplasty or stenting provided the most favora

236 lesions located in the IMA graft, by either balloon angioplasty or stenting.

237 native coronary artery to paclitaxel-coated balloon angioplasty or uncoated balloon angioplasty.

238 atment paradigm of MS involving endovascular balloon angioplasty or venous stent placement has been p

239 ronary intervention (PCI) either by means of balloon angioplasty or with the use of bare-metal stents

240 ar brachytherapy, and 18.0% for conventional balloon angioplasty (P=0.57).

241 62.7% (95% CI: 50.0%, 73.0%) of conventional balloon angioplasty participants (P < .001).

242 d 78% (95% CI: 66.5%, 86.0%) of conventional balloon angioplasty participants (P = .001).

243 One DCB angioplasty and two conventional balloon angioplasty participants died (risk ratio, 0.48;

244 blation yields improved clinical results for balloon angioplasty (percutaneous transluminal coronary

245 outcomes of coronary stenting with those for balloon angioplasty (percutaneous transluminal coronary

246 nd higher 1-year mortality than conventional balloon angioplasty (percutaneous transluminal coronary

247 s in the 4 treatment groups were as follows: balloon angioplasty/placebo, 14.2%; stent/placebo, 15.8%

248 (hazard ratio, 0.74; P=0.006) compared with balloon angioplasty/placebo, respectively.

249 Relative to stenting plus placebo and balloon angioplasty plus abciximab, the incremental 1-ye

250 undergo either balloon angioplasty alone or balloon angioplasty plus placement of the stent graft.

251 tenting (DS) and 3,176 patients treated with balloon angioplasty plus stenting (BA+S).

252 (DCBA) was shown to be superior to standard balloon angioplasty (POBA) in terms of restenosis preven

253 us coronary intervention (PCI) (43 plain old balloon angioplasty [POBA] and 41 DES) were analyzed to

254 f A20 to medial rat carotid artery SMC after balloon angioplasty prevents neointimal hyperplasia by b

255 threatened closure after failed conventional balloon angioplasty procedures.

256 Balloon angioplasty produced a large decrease in both th

257 eated with surgical revascularization versus balloon angioplasty, prompting a National Heart Lung and

258 lysis followed by percutaneous transluminal balloon angioplasty (PTA) and stenting for residual ilia

259 al SES stenting or percutaneous transluminal balloon angioplasty (PTA).

260 (n=1703) were randomized to stenting versus balloon angioplasty (PTCA) and abciximab versus no abcix

261 ment in early or late outcomes compared with balloon angioplasty (PTCA).

262 patients with AMI were randomized to undergo balloon angioplasty (PTCA, n=448) or coronary stenting (

263 12 hours of symptom onset were randomized to balloon angioplasty (PTCA; n=518), PTCA+abciximab (n=528

264 tive of revascularization strategy (stent or balloon angioplasty), resulted in a significant reductio

265 dovascular irradiation at 15Gy or 30Gy after balloon angioplasty results in incomplete endothelial re

266 Among those who advocate balloon angioplasty, some recommend dilation only of rec

267 Because stents reduce restenosis compared to balloon angioplasty, stent use has increased significant

268 Interventions such as balloon angioplasty, stenting, and surgical revascularis

269 nting as part of a percutaneous transluminal balloon angioplasty strategy has equivalent 1-year paten

270 entified shock, peripheral vascular disease, balloon angioplasty strategy, and unstable angina as ind

271 accelerated reendothelialization at sites of balloon angioplasty, suggesting an important physiologic

272 alpha) at the sites of arterial injury after balloon angioplasty, suppresses endothelial cell (EC) pr

273 Balloon angioplasty, the first-line therapy, has a tende

274 rat left carotid arteries were injured using balloon angioplasty to cause neointimal hyperplasia.

275 eas of old technology reviewed are (1) using balloon angioplasty to palliate low birth weight infants

276 itioning (PC) or an unrestricted approach to balloon angioplasty (UC).

277 was administered to the site of a successful balloon angioplasty using a microporous local delivery i

278 Balloon angioplasty, validated at pre- and postoperative

279 view (meta-analysis) of randomized trials of balloon angioplasty versus coronary atherectomy, laser a

280 et undergoing primary PCI were randomized to balloon angioplasty versus stenting, each +/- abciximab.

281 ted in 1,301 patients with AMI randomized to balloon angioplasty versus stenting, each with or withou

282 is small series, PA stent fracture using UHP balloon angioplasty was feasible and did not result in m

283 In drug-eluting stent ISR, balloon angioplasty was inferior to everolimus-eluting s

284 Balloon angioplasty was limited by unpredictable procedu

285 Balloon angioplasty was performed in all patients, follo

286 Balloon angioplasty was performed on the iliac arteries

287 Balloon angioplasty was successful (gradient <10 mm Hg)

288 Drug-coated balloon angioplasty was superior to standard angioplasty

289 classification scheme dates from an era when balloon angioplasty was the only percutaneous treatment

290 Cutting balloon angioplasty was used in 46% (25/54) of cases, an

291 d in-patient mortality, but patients who had balloon angioplasty were, on average, 1.36 times more li

292 ibition of IH in various animal models (e.g. balloon angioplasty, wire injury, and vein graft), but v

293 h abciximab, compared with stenting alone or balloon angioplasty with abciximab, is associated with i

294 ng with abciximab, stenting with placebo, or balloon angioplasty with abciximab.

295 s study was designed to compare conventional balloon angioplasty with an expanded polytetrafluoroethy

296 derwent successful percutaneous transluminal balloon angioplasty with an iodinated contrast medium (2

297 ith atherectomy, laser, or atherotomy versus balloon angioplasty with or without coronary stenting.

298 (14 events, 6.1%) than with the strategy of balloon angioplasty with provisional stenting (37 events

299 utcomes at a cost similar to that of initial balloon angioplasty with provisional stenting.

300 (Paclitaxel-Eluting Balloon Angioplasty With Provisional Use of Nitinol Sten